一季报落幕,沪市一批医药龙头企业首季展现出的业绩也提振人心。 数据显示,沪市主板111家医药类公司2026年一季度合计实现营业收入3305.5亿元,同比小幅上升2%,合计实现净利润247亿元,同比上升0.5%。其中,药明康德、恒瑞医药分别贡献了超过46.5亿元和22.8亿元的净利润,两公司均实现了一季度营收、净利润的显著增长,为整个行业首季表现提供了强力支撑。 在行业整体仍面临控费压力、创新药...
Source Link一季报落幕,沪市一批医药龙头企业首季展现出的业绩也提振人心。 数据显示,沪市主板111家医药类公司2026年一季度合计实现营业收入3305.5亿元,同比小幅上升2%,合计实现净利润247亿元,同比上升0.5%。其中,药明康德、恒瑞医药分别贡献了超过46.5亿元和22.8亿元的净利润,两公司均实现了一季度营收、净利润的显著增长,为整个行业首季表现提供了强力支撑。 在行业整体仍面临控费压力、创新药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.